



GPX medical

Presentation of Year-end Report
January-December 2020

2021-02-16



ABOUT GPX MEDICAL

- Develops new pediatric medical device to meet an extensive clinical need
- A growing addressable market of 586 million Euros (USA, Germany, France, UK)
- Strong clinical support
- Proven, commercialized technology with platform potential
- Headquarter in Lund, listed on Nasdaq First North Growth Market Stockholm (Ticker: GPXMED)



Improves the neonatal intensive care

- Proven and patented technology called biomedical GASMAS.
- Continuous non-invasive monitoring of the lungs of preterm born infants.
- Measures lung volume and oxygen gas concentration.
- Realtime alert at life-threatening complications for objective decision making.

Market potential



Rising trend in preterm births



Global market worth 2,5 billion USD



Growing patient group



First market - 586 million EUR

Business model



Hospital

- System
- Disposable items
- Maintenance/Service



Industrial companies

- Integration in ventilators
- Licensing model
- Reach global market rapidly

LISTING ON NASDAQ FIRST NORTH GROWTH MARKET STOCKHOLM



GASPOROX
LASER SENSOR PACKAGE SOLUTIONS



Selection of important events



Pre-clinical study
Big steps within
product development



Two new Patent
applications



Scientific article
published



Medical Advisor
- Neonatologist Pontus
Johansson



Strengthened
organization:
- Product development
- Clinical
- Commercial

New major owner



”GPX Medical is an innovative medical technology company that develops an important product for neonatal intensive care with great potential in a significant global market. We strongly believe in the company’s management and the commercial focus that the company has. As long-term owners, we are pleased to have the opportunity to include this holding in our investment portfolio, and to support GPX Medical’s path towards commercialization and global market launch.”

- Masoud Khayyami, boardmember and founder of Cardeon





Fourth quarter, October-December 2020
Accelerated product development towards certification of NEOLA®

Summary of GPX Medical's fourth quarter of 2020 (October-December)

Operating income amounted to 877 tkr (916)

Operating profit amounted to -2 005 tkr (-961)

Cash flow for the period amounted to 15 503 tkr (-1 357)

Earnings per share amounted to -0,19 kr (-0,14)

Full year, Januari-December 2020
Grants, listing at Nasdaq First North and accelerated product development

Summary of the full year of 2020 for GPX Medical

Operating income amounted to 2 922 tkr (2 830)

Operating profit amounted to -6 715 tkr (-2 606)

Cash flow for the period amounted to 11 291 tkr (-4 505)

Earnings per share amounted to -0,85 kr (-0,37)

Cash and cash equivalents amounted to 16 646 tkr (5 355)

Net liquidity from rights issue amounted to 20 167 tkr in the beginning of October

Acceleration and milestones for technical product development

Financial development during the reporting period

	2020-10-01 -2020-12-31	2019-10-01 -2019-12-31	2020-01-01 -2020-12-31	2019-01-01 -2019-12-31
GPX Medical in summary	3 months	3 months	12 months	12 months
Operating income (tkr)	877	916	2 922	2 830
EBIT, operating profit (tkr)	-2 005	-961	-6 715	-2 606
Cash flow of the period (tkr)	15 503	-1 357	11 291	-4 505
Cash and cash equivalents (tkr)			16 646	5 355
Equity per share before dilution (kr)			2,24	128,68
Equity ratio (%)			91	88
Balance sheet total (tkr)			25 967	12 225
Quick ratio (%)			720	390
Average number of shares before dilution (st)	10 524 990	6 999 972	7 897 239	6 999 972
Earnings per share before dilution (kr)	-0,19	-0,14	-0,85	-0,37
Number of shares at the end of the period (st)	10 524 990	83 333	10 524 990	83 333

- Operating income amounted to 2 922 tkr and consisted of balanced development costs and innovation grants.
- Operating costs during the period amounted to approx. 9,6 msek of which 1,6 msek was one-time pre-stock exchange costs. Underlying burnrate amounted to approx. 800 tsek per month.
- Net liquidity from rights issue amounted to approx. 20,1 msek. Burnrate during year 2021 is expected to amount to over 1 msek per month and gradually increases as we enter the intensive product development phase.

Milestones




Validation 2022



Launch 2023



Quality Management System



Clinical validation



CE marking & FDA



Key Opinion Leaders



Market preparations



Build Organization

Our way to market



Summary and closing remarks

- Eventful year for GPX Medical
- We follow our established plans for the product development
- We prepare for commercialization
- We see a large interest from clinics, distributors and industry
- We welcome our new shareholders and investors, thank you for the trust!





Contact

CEO Hanna Sjöström

Hanna.Sjostrom@gpxmedical.se

CFO Urban Ottosson

Urban.ottosson@gpxmedical.se

Follow us on social media!



<https://www.gpxmedical.se>



<https://www.facebook.com/gpxmedical>



<https://www.linkedin.com/company/gpx-medical>



<https://twitter.com/gpxmed>